Portal Vein Embolization in Treating Patients With Liver Metastases From Primary Colorectal Cancer

This study has been completed.
Information provided by:
Memorial Sloan-Kettering Cancer Center
ClinicalTrials.gov Identifier:
First received: January 4, 2002
Last updated: June 4, 2013
Last verified: June 2013

January 4, 2002
June 4, 2013
August 2001
January 2004   (final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT00028626 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Portal Vein Embolization in Treating Patients With Liver Metastases From Primary Colorectal Cancer
Clinical Efficacy And Biologic Effects Of Preoperative Portal Vein Embolization In Patients With Colorectal Liver Metastases

RATIONALE: Embolization blocks blood flow to part of an organ and/or tumor. Blocking the portal vein on one side of the liver may cause the opposite side of the liver to increase in size and decrease the risk of liver failure following surgery.

PURPOSE: Phase II trial to study the effectiveness of portal vein embolization in treating patients who have liver metastases from primary colorectal cancer.


  • Determine whether portal vein embolization results in significant hypertrophy of the remaining liver and potentially decreases the risk of liver failure after hepatic resection in patients with liver metastases from primary colorectal cancer.
  • Determine the biologic effects of this therapy on liver metastases and normal liver parenchyma in these patients.

OUTLINE: Patients undergo portal vein embolization with 200-300 micron polyvinyl chloride particles suspended in Iohexol 300. Approximately 3-6 weeks after embolization, patients undergo an exploratory laparotomy followed by hepatic surgical resection.

Patients are followed for at least 6 months.

PROJECTED ACCRUAL: A total of 25 patients will be accrued for this study.

Phase 2
Primary Purpose: Treatment
  • Colorectal Cancer
  • Metastatic Cancer
Drug: embolization therapy
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
Not Provided
January 2004
January 2004   (final data collection date for primary outcome measure)


  • Histologically confirmed primary colorectal adenocarcinoma with metastases to the liver being considered for hepatic resection
  • Requirement for removal of at least 60% of functional liver parenchyma based on CT scan
  • No extrahepatic disease by laparoscopy



  • Over 18

Performance status:

  • ECOG 0-2

Life expectancy:

  • Not specified


  • WBC at least 2,000/mm3
  • Platelet count at least 100,000/mm3


  • Bilirubin no greater than 1.8 mg/dL
  • AST and ALT no greater than 80 IU/L


  • Creatinine no greater than 1.8 mg/dL


  • No New York Heart Association class III or IV heart disease


  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception


Biologic therapy:

  • Not specified


  • At least 1 month since prior systemic chemotherapy

Endocrine therapy:

  • Not specified


  • Not specified


  • See Disease Characteristics


  • At least 2 months since prior investigational treatment
18 Years and older
Contact information is only displayed when the study is recruiting subjects
United States
01-113, CDR0000069112, NCI-G01-2039
Not Provided
Not Provided
Memorial Sloan-Kettering Cancer Center
National Cancer Institute (NCI)
Study Chair: Ronald DeMatteo, MD Memorial Sloan-Kettering Cancer Center
Memorial Sloan-Kettering Cancer Center
June 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP